| BTP | 57227-09-5 | In-house | Tiropramide Intermediate | Commercialized | 
                            
                    | RV-142 | 84611-22-3 | In-house | Erdosteine Intermediate | Commercialized | 
                            
                    | N-Lauroyl-L-lysine | 52315-75-0 | In-house | Cosmetic Ingredient | Commercialized | 
                            
                    | PDRN (polydeoxyribonucleotide) | 100403-24-5 | 50 ~ 1,500 kDa | Repairing, anti-inflamation, anti-aging | Commercialized. DMF be finished by Mid of 2026
 | 
                            
                    | PN (polynucleotide) | 100403-24-5 | 100 ~ 2,000 kDa | Repairing, anti-inflamation, anti-aging | Commercialized. DMF be finished by Mid of 2026
 | 
                            
                    | PDLLA (Poly(DL-lactic acid)) | 26680-10-4, 51056-13-9 | 0.16~2.7 dl/g | Microsphere used for medical beauty filler | Commercialized |